About HEC CJ PHARM Company

Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd. is a pharmaceutical enterprise focusing on R&D, production and sales of pharmaceutical products in the fields of anti-infective, endocrine and metabolic disease treatment. It is a domestic pharmaceutical platform under the Dongyangguang Group. The company entered the Chinese pharmaceutical industry through its predecessor, Yichang Changjiang Pharmaceutical Co., Ltd., which was established in 2001. Up to now, we have more than 23 years of business history, and our pharmaceutical sales performance and R&D capabilities rank among leading domestic pharmaceutical companies. On May 11, 2015, the Company was restructured as a company limited by shares and successfully listed on the main board of the Hong Kong Stock Exchange on December 29, 2015, stock code: 01558.HK. Since its establishment, the company has always adhered to the pharmaceutical concept of “serving the Chinese with higher standards”, and has a strong industrial base and leading competitive advantage in pharmaceutical manufacturing and marketing. As of December 31, 2023, the company had a nationwide product distribution network and 1,788 professional sales personnel. One of the company's core products, Kewei (oseltamivir phosphate), is a first-line drug for clinical use against influenza virus in China. It has strong brand power and continues to maintain its preferred position in the influenza field. Oseltamivir phosphate was included in the “National Catalogue of Essential Medicines (2018 Edition)” in 2018. In 2020, oseltamivir phosphate continued to be selected for the “Influenza Diagnosis and Treatment Plan (2020 Edition)” issued by the General Office of the National Health Commission. In 2023, oseltamivir phosphate products continued to be included in the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2023 Edition)” issued by China's Ministry of Human Resources and Social Security. In addition, the company has established strategic partnerships with many well-known pharmaceutical companies: a strategic partnership was reached with Sinopharm Pharmaceutical Co., Ltd. (Shenzhen Stock Exchange: 000028.SZ), and the first operating project was officially launched in 2018; a strategic cooperation framework agreement was signed with Jiuzhou Tong Pharmaceutical Group Co., Ltd. (“Kyushu Express”). Based on this, the company authorized the exclusive agency for the OTC channel of Kyushu Connect in mainland China; with the Wuhan Institute of Virology of the Chinese Academy of Sciences, National Emergency Prevention and Control Drug Engineering Technology Research The Center and Guangdong Dongyangguang Pharmaceutical Co., Ltd. (formerly known as Guangdong Dongyangguang Pharmaceutical Co., Ltd., “Guangdong Dongyangguang Pharmaceutical”) signed an agreement of intent. Based on this, all parties will jointly establish a national civil-military integration collaborative industrialization platform for emergency prevention and control drugs and a national antiviral drug center. The company believes that the above strategic partnership will bring ideal development prospects to the company's business. The company always adheres to the implementation of specialized, branded and differentiated development strategies, and is committed to the professional development of the marketing team, steady and innovative market operation and strategic resource integration to create the unique brand characteristics and core competitiveness of “Dongyang Yangtze Pharmaceutical” within the industry, and create more value for pharmaceutical consumers and partners. In the future, the company will further develop and enrich the product line, open up the market and improve the production standards and quality of products, and continue to expand the scope of marketing and sales coverage to promote further growth in the company's business and profitability, and seek more economic benefits and benefits for investors.